Table 3.
Characteristics of Patients with GBS According to Remnant Cholesterol Quartile.
| Remnant cholesterol, mmol/L | P Trend | |||||
|---|---|---|---|---|---|---|
| Characteristics | All patients | Q1 (<0.37) | Q2 (0.37-0.49) | Q3 (0.49-0.62) | Q4 (>0.62) | |
| Patients | 147 | 33 | 40 | 35 | 39 | |
| Age, years | 48.0 (33.0-60.0) | 39.0 (25.0-60.0) | 43.5 (29.3-61.0) | 52.0 (36.0-60.0) | 52.0 (44.0-60.0) | 0.033 |
| Sex, male | 82 (55.8) | 18 (54.5) | 22 (55) | 16 (45.7) | 26 (66.7) | 0.676 |
| WBC count, 109/L | 6.38 ± 2.20 | 7.07 ± 2.29 | 8.25 ± 3.36 | 7.82 ± 2.36 | 7.82 ± 2.36 | 0.003 |
| Lymphocyte count, 109/L | 1.69 ± 0.64 | 1.74 ± 0.59 | 1.96 ± 0.87 | 2.06 ± 1.08 | 2.06 ± 1.08 | 0.141 |
| Monocyte count, 109/L | 0.40 ± 0.15 | 0.49 ± 0.19 | 0.54 ± 0.27 | 0.50 ± 0.22 | 0.50 ± 0.22 | 0.029 |
| GBS disability score at entry | 0.002 | |||||
| 0 or 1 | 9 (6.1) | 1 (3.0) | 6 (15.0) | 1 (2.9) | 1 (2.6) | |
| 2 | 47 (32.0) | 20 (60.6) | 17 (42.5) | 3 (8.6) | 7 (17.9) | |
| 3 | 45 (30.6) | 4 (12.1) | 7 (17.5) | 14 (40.0) | 20 (51.3) | |
| 4 | 40 (27.2) | 6 (18.2) | 9 (22.5) | 17 (48.5) | 8 (20.5) | |
| 5 | 6 (4.1) | 2 (6.0) | 1 (2.5) | 0 (0) | 3 (7.7) | |
| GBS disability score at discharge | < 0.001 | |||||
| 0 or 1 | 55 (37.4) | 18 (54.5) | 23 (57.5) | 5 (14.3) | 9 (23.1) | |
| 2 | 40 (27.2) | 8 (24.3) | 10 (25.0) | 10 (28.6) | 12 (30.8) | |
| 3 | 30 (20.4) | 4 (12.1) | 4 (10.0) | 11 (31.4) | 11 (28.2) | |
| 4 | 18 (12.3) | 2 (6.1) | 2 (5.0) | 9 (25.7) | 5 (12.8) | |
| 5 | 4 (2.7) | 1 (3.0) | 1 (2.5) | 0 (0) | 2 (5.1) | |
| Disease remission score | 0.079 | |||||
| 0 | 53 (36.1) | 8 (24.2) | 11 (27.5) | 17 (48.6) | 17 (43.6) | |
| 1 | 75 (51.0) | 21 (63.6) | 22 (55.0) | 13 (37.1) | 19 (48.7) | |
| 2 | 18 (12.2) | 4 (12.1) | 7 (17.5) | 5 (14.3) | 2 (5.1) | |
| 3 | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) | 1 (2.6) | |
| MRC sum score | 44.90 ± 15.09 | 48.67 ± 11.55 | 46.95 ± 15.71 | 43.51 ± 13.42 | 40.85 ± 17.69 | 0.022 |
| 24-h intrathecal IgG | 3.18 (-0.21-19.29) | 2.24 (0.27-22.58) | 6.75 (0.31-24.05) | 3.94 (-9.08-17.24) | 2.62 (-7.77-8.98) | 0.188 |
| CSF-ALB, mg/dl | 0.37 (0.24-0.71) | 0.35 (0.24-0.63) | 0.39 (0.20-0.71) | 0.43 (0.22-0.78) | 0.33 (0.26-0.81) | 0.448 |
| Serum-ALB, mg/dl | 38.37 ± 6.74 | 39.66 ± 6.18 | 39.93 ± 8.45 | 36.06 ± 4.68 | 37.37 ± 5.94 | 0.017 |
| CSF-IgG, mg/ml | 0.063 (0.036-0.183) | 0.058 (0.035-0.149) | 0.575 (0.28-0.160) | 0.096 (0.039-0.25) | 0.062 (0.038-0.215) | 0.292 |
| Serum-IgG, mg/ml | 12.95 (10.40-24.53) | 12.80 (11.30-19.80) | 11.4 (10.23-16.70) | 19.95 (11.70-31.20) | 13.90 (9.88-25.85) | 0.308 |
| CSF-Pro, mg/dl | 59.25 (38.80-110.64) | 53.90 (38.35-89.55) | 57.48 (31.45-110.81) | 72.38 (36.24-134.07) | 53.3 (39.34-133.52) | 0.215 |
| CSF-WBC,/ul | 4.0 (2.0-7.5) | 5.0 (2.0-9.0) | 3.5 (2.0-6.75) | 4.5 (2.0-5.25) | 3.0 (2.0-7.5) | 0.223 |
| Albuminocytologic dissociation | 0.522 | |||||
| Yes | 62 (42.2) | 15 (48.4) | 14 (35) | 13 (28.9) | 20 | |
| No | 85 (57.8) | 18 (52.6) | 26 (65) | 22 (71.1) | 19 | |
WBC, white blood cell; CSF, cerebrospinal fluid; ALB, albumin; 24-h intrathecal IgG, intrathecal Immunoglobulin G synthesis rate of 24 hours;Pro, total protein.